• Liproxstatin-1 HCl: Redefining Ferroptosis Assays with Preci

  2026-07-09

  Explore how Liproxstatin-1 HCl, a potent ferroptosis inhibitor, enables next-generation lipid peroxidation research. This article uniquely examines the molecule’s mechanistic selectivity and protocol optimization, revealing deeper insights for acute renal failure and hepatic injury models.

• Caspase-4 Colorimetric Assay Kit: Precision in Pyroptosis Re

  2026-07-09

  Uncover robust, quantitative detection of caspase-4 activity with the Caspase-4 Colorimetric Assay Kit, enabling streamlined workflows for probing inflammation, pyroptosis, and organelle-targeted cell death. This guide delivers actionable protocol enhancements, troubleshooting insights, and translational context grounded in recent ER-targeted self-assembly research.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-07-08

  The referenced study reports the discovery of a new class of allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with lead compound 8c demonstrating potent in vitro and in vivo efficacy. These findings highlight therapeutic opportunities for diabetes, allergic disorders, and cancer, offering a structurally novel scaffold for future drug development.

• FLOT1–FOSL2–EphA2 Axis Drives Microglial Polarization in AD

  2026-07-08

  This study elucidates how the interaction between FLOT1 and FOSL2 promotes EphA2 transcription, activating the p38/MAPK pathway and driving pro-inflammatory microglial polarization in Alzheimer’s disease models. The findings provide new mechanistic insight into neuroinflammation in AD and highlight the FLOT1–FOSL2–EphA2 axis as a promising therapeutic target.

• Moxibustion Promotes Axonal Regeneration via PI3K/Akt Modula

  2026-07-07

  This study demonstrates that moxibustion enhances axonal regeneration and cognitive recovery in post-stroke rats by activating the PI3K/Akt pathway and upregulating TACC3. The use of LY294002 as a pathway inhibitor confirms the central mechanistic role of PI3K/Akt signaling in these neurorestorative effects, providing a controlled framework for future investigations of post-stroke cognitive impairment therapies.

• Chemerin in cNTS Drives Sympathetic Activity via Superoxide

  2026-07-07

  This study elucidates how chemerin engages CMKLR1 signaling in the caudal nucleus tractus solitarius (cNTS) to elevate sympathetic nerve activity and blood pressure through NADPH oxidase–mediated superoxide production, not via AMPA/kainate glutamate receptors. The findings clarify receptor specificity in central cardiovascular regulation and refine strategies for dissecting glutamatergic versus redox mechanisms in neurocardiology research.

• Protease Inhibitor Cocktail (100X H₂O, EDTA Plus): Mechanism

  2026-07-06

  The Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) is a protein stability enhancer designed to inhibit broad classes of proteases during protein extraction. This dossier reviews its mechanism of action, application scope, and experimental best practices for ensuring high-fidelity protein studies.

• Toremifene in Breast Cancer: Two Decades of Clinical Insight

  2026-07-06

  This review critically examines 20 years of clinical data on toremifene, a selective estrogen receptor modulator (SERM), highlighting its efficacy, safety, and unique pharmacokinetic profile in the treatment of estrogen receptor-positive breast cancer. The findings underscore the importance of biomarker-driven, individualized therapy selection and illuminate the comparative roles of SERMs and aromatase inhibitors in breast cancer management.

• Metal-Ion-Chelating l-Phe Nanostructures Enhance ICB Immunot

  2026-07-05

  This study introduces metal-ion-chelating l-phenylalanine nanostructures as a strategy to overcome immune dysfunction and sensitize breast tumors to immune checkpoint blockade. By modulating dendritic cell ion channel activity and leveraging short-term starvation, the approach remodels the tumor microenvironment to promote antitumor immunity, providing a mechanistic foundation for improving cancer immunotherapy outcomes.

• Isradipine (Dynacirc): Pushing Boundaries in Calcium Channel

  2026-07-04

  Explore how Isradipine (Dynacirc) advances calcium channel research as both a precise L-type blocker and a tool for decoding neuroprotective mechanisms. This article reveals nuanced assay strategies and practical implications that set it apart from existing guides.

• Partial β-Secretase Inhibition Preserves Synaptic Transmissi

  2026-07-03

  Satir et al. (2020) demonstrate that moderate reduction of amyloid β (Aβ) production via β-secretase inhibitors does not impair synaptic transmission in cultured neurons. These findings inform the design of future Alzheimer’s disease interventions, suggesting that partial rather than complete suppression of Aβ may maximize safety and efficacy.

• Fulvestrant (ICI 182,780): Deep Mechanistic Insights for Adv

  2026-07-03

  Explore Fulvestrant (ICI 182,780) as a next-generation tool in ER-positive breast cancer research. This article provides new scientific depth on its mechanism, unique post-translational effects, and translational value for overcoming endocrine therapy resistance.

• BCL-XL Inhibitor A-1155463: Precision Tools for Apoptosis Re

  2026-07-02

  A-1155463 empowers cancer researchers with unparalleled selectivity in targeting BCL-XL-dependent survival, facilitating robust apoptosis induction and tackling drug resistance in challenging tumor models. Explore advanced experimental workflows, practical troubleshooting, and comparative insights for maximizing the impact of this potent, selective BCL-XL inhibitor from APExBIO.

• E-64d: Applied Cysteine Protease Inhibition in Cell Fate Stu

  2026-07-02

  E-64d, a membrane-permeable cysteine protease inhibitor, enables researchers to dissect regulated cell death pathways with high precision in both cellular and in vivo models. Its robust inhibition of calpain and cathepsins uniquely positions E-64d for advanced neuroprotection, apoptosis, and platelet signaling research.

• A Drug-Sensitized Yeast System for mTOR Inhibitor Discovery

  2026-07-01

  This study introduces a highly sensitive yeast-based platform for identifying mTOR pathway inhibitors, leveraging drug-sensitized strains with impaired efflux mechanisms. The approach enables rapid, cost-efficient screening of candidate compounds and clarifies the mechanistic specificity of diverse small molecules, providing a benchmark for metabolic research assay selectivity.

454 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page